Text
Situasi Paten Obat Anti Diabetes, Anti Hipertensi, Anti Malaria dan Anti Tuberkulosis di Indonesia
Indonesia is the fourth most populous country after China, India and America. There has been an epidemiological transition. While the prevalence of infectious diseases such as malaria, tuberculosis and dengue fever is still high, the incidence of non-communicable diseases is increasing. High rates of morbidity becomes good opportunity to develop medicine for infectious diseases as well as non-communicable diseases to get patent because of a very large market share. Unfortunately, the vast market potential is only captured by foreign countries. Data from the Directorate General of Intellectual Property Rights (IPR DG) in 2010 showed that domestic patent applicants who get approval (granted) were only 4.6% while overseas were 92.03%. This situation is very ironic, since Indonesia is a country with potential basic ingredient of natural medicines and the third highest biodiversity after Brazil and China.
The aim of this study was to evaluate patent situation of medicine registered in IPR DG, Law & Human Rights Ministry in the last 7 years (2005 to 2011) for infectious diseases (malaria and tuberculosis) and non communicable (hypertension and diabetes). This study used observational method by tracing patent documents from web addresses of the relevant agencies. It showed that Indonesia only registered 4.9% patent from all patents registered in IPR DG from 2005 to 2011. Indonesia only registered 3.4% from 89 patents for anti-hypertension, 4.8% from 250 patents for anti-diabetic, and 21.1% from 18 patents for anti-malaria, and 7.1% from 14 patents for antituberculosis. Most of the patents filled or registered by Indonesian registrant is a patent medicine of herbs’ extract or its composition, it was concluded that medicine patents for non-communicable diseases and infectious diseases in Indonesia are dominated by foreign country.
Keywords : Patent situation, medicine, IPR-DG, Indonesia
No other version available